Metoprolol Hexal Z (Metoprolol Succinate)

Metoprolol Hexal Z is a beta‑adrenergic blocker used in several cardiovascular conditions.

• Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output.
• Angina pectoris: lowers myocardial oxygen demand, relieving chest pain during exertion.
• Chronic heart failure: improves survival and reduces hospitalisation by moderating heart rate and contractility.
• Post‑myocardial infarction prophylaxis: decreases the risk of recurrent cardiac events through heart‑rate control.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting the effects of endogenous catecholamines. This blockade reduces heart rate, myocardial contractility, and conduction velocity, leading to lower cardiac output and decreased arterial pressure, while also diminishing myocardial oxygen consumption.

Metoprolol Hexal Z may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Cold extremities
• Gastrointestinal upset (nausea, abdominal discomfort)
• Sleep disturbances (insomnia or vivid dreams)

Serious or Rare Side Effects

• Bradycardia (excessively slow heart rate)
• Hypotension (significant blood‑pressure drop)
• Heart block or atrioventricular conduction abnormalities
• Worsening of heart failure symptoms
• Severe bronchospasm in patients with underlying airway disease

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.

• Cardiovascular assessment: evaluate baseline heart rate, blood pressure and cardiac function.
• Respiratory status: avoid in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.
• Diabetes monitoring: watch for masking of hypoglycaemia symptoms.
• Concomitant medications: review for potential additive bradycardic or hypotensive agents.
• Renal/hepatic impairment: adjust dosing or monitor closely in reduced organ function.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metoprolol Hexal Z can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective β‑blockers or other cardio‑depressant agents (risk of profound bradycardia).
• Calcium channel blockers such as verapamil or diltiazem (enhanced AV‑node blockade).
• Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine) leading to increased metoprolol exposure.

Moderate Interactions (Monitor Closely)

• Antidiabetic drugs (may mask hypoglycaemia symptoms).
• NSAIDs (potential reduction of antihypertensive effect).
• Antidepressants with serotonergic activity (possible additive dizziness).